| Not Yet Recruiting | Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients NCT07247201 | Singapore General Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center NCT07413146 | Sun Yat-sen University | N/A |
| Not Yet Recruiting | Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC NCT07350824 | Tongji Hospital | N/A |
| Recruiting | A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cance NCT07136077 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigen NCT07291921 | Peking University People's Hospital | — |
| Not Yet Recruiting | Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for P NCT06941987 | Shanghai Zhongshan Hospital | — |
| Recruiting | Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer NCT06930807 | Peking University People's Hospital | N/A |
| Not Yet Recruiting | NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL NCT06763302 | The Children's Hospital of Zhejiang University School of Medicine | N/A |
| Recruiting | Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in C NCT06358430 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS NCT06536959 | Beijing 302 Hospital | Phase 2 |
| Not Yet Recruiting | Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax NCT06090786 | Gruppo Italiano Malattie EMatologiche dell'Adulto | N/A |
| Recruiting | French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC) NCT06287814 | University Hospital, Montpellier | — |
| Not Yet Recruiting | Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (E NCT06323148 | Fudan University | Phase 3 |
| Recruiting | French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC) NCT06287749 | University Hospital, Montpellier | — |
| Not Yet Recruiting | French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM) NCT06287723 | University Hospital, Montpellier | — |
| Recruiting | Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not NCT06463717 | First Affiliated Hospital of Zhejiang University | — |
| Recruiting | CtDNA Based MRD Testing for NAC Monitoring in TNBC NCT06230185 | Personalis Inc. | — |
| Recruiting | A Study of Chidamide With AZA in MRD Positive AML After Transplant NCT06066905 | Guangdong Provincial People's Hospital | N/A |
| Recruiting | Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil NCT05959720 | Instituto do Cancer do Estado de São Paulo | — |
| Completed | Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia NCT05987696 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Unknown | Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology NCT05969938 | WeiWei Xiao | — |
| Unknown | Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA NCT05900583 | Guangdong Provincial People's Hospital | — |
| Recruiting | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Minimally Residual of Esophageal Cancer 001 NCT05952661 | Hebei Medical University Fourth Hospital | — |
| Unknown | A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Pos NCT05603156 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Terminated | Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease NCT05601830 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Completed | A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) NCT05429320 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloi NCT05362942 | Beijing 302 Hospital | Phase 2 |
| Unknown | Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD) NCT04604691 | Seoul National University Hospital | Phase 1 |
| Recruiting | A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persist NCT06109233 | FengYan Jin | — |
| Unknown | Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation NCT05460195 | Shanghai Chest Hospital | Phase 2 |
| Recruiting | Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MR NCT05408897 | Peking University People's Hospital | — |
| Unknown | Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD NCT05137860 | Hospital General de Mexico | Phase 4 |
| Completed | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor NCT04853017 | Elicio Therapeutics | Phase 1 |
| Completed | Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia NCT05093192 | University of Bath | N/A |
| Terminated | Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML) NCT04920188 | UNC Lineberger Comprehensive Cancer Center | — |
| Recruiting | Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients NCT06885476 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A |
| Completed | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat NCT04712942 | University of Leipzig | Phase 2 |
| Terminated | ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT NCT04785547 | Prof. Christina Peters | Phase 2 |
| Terminated | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig NCT03272633 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Terminated | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant NCT04044560 | University of British Columbia | Phase 2 |
| Terminated | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After NCT03537599 | Sumithira Vasu | Phase 1 / Phase 2 |
| Recruiting | Better Leukemia Diagnostics Through AI (BELUGA) NCT04466059 | Munich Leukemia Laboratory | — |
| Active Not Recruiting | Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemi NCT03516279 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Completed | Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases NCT06404593 | Peking University Cancer Hospital & Institute | — |
| Withdrawn | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, NCT04029038 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leuk NCT03699384 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Unknown | The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML NCT03665480 | Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 |
| Unknown | Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-tran NCT03624530 | Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 |
| Suspended | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treatin NCT03494569 | City of Hope Medical Center | Phase 1 |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refrac NCT03241940 | Stanford University | Phase 1 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refract NCT03233854 | Stanford University | Phase 1 |
| Active Not Recruiting | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus H NCT03192397 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Unknown | Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotrans NCT03297528 | Peking University People's Hospital | Phase 2 |
| Terminated | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia NCT02767934 | University of Washington | Phase 2 |
| Completed | MRD-directed Therapy for Low-risk and Intermediate-risk AML. NCT02870777 | Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 |
| Completed | MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT NCT02673008 | Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 |
| Completed | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies NCT02529813 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT02159495 | City of Hope Medical Center | Phase 1 |
| Completed | Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease NCT02458014 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia NCT02714790 | A.O.U. Città della Salute e della Scienza | — |
| Completed | Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Canc NCT02314871 | The Institute of Molecular and Translational Medicine, Czech Republic | Phase 4 |
| Unknown | Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors NCT02400970 | University Hospital, Clermont-Ferrand | — |
| Unknown | Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors NCT02400827 | University Hospital, Clermont-Ferrand | — |
| Unknown | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leuke NCT01894477 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Ther NCT01751425 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive NCT01883219 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Completed | Validation of a Method to Search Residual Disease in Auto-cryopreserved Ovarian Tissues NCT02900625 | Centre Hospitalier Universitaire de Besancon | — |
| Recruiting | Caris Biorepository Research Protocol NCT01499394 | Caris Science, Inc. | — |
| Terminated | Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia NCT01158885 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 2 |
| Completed | Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease NCT00267085 | M.D. Anderson Cancer Center | Phase 2 |